Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study will enroll participants who have been diagnosed with type 2 diabetes and are
experiencing symptoms of depression. This study will look at an anti-depressant medication
called vortioxetine (Trintellix). Vortioxetine is an oral medication (pill) that has been
approved by the US Food and Drug Administration (FDA) to treat depression in adults.
The purpose of this study is to look at what effects (if any) vortioxetine may have on
symptoms of depression in patients with type 2 diabetes. This study will also look at what
effects (if any) vortioxetine has on blood sugar, and how vortioxetine may improve the way
our brains are able to adapt and respond to stress.